AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • August 9th, 2019 • Voyager Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Amended and Restated Employment Agreement (this “Agreement”) is made as of May 20, 2019 (the “Effective Date”) by and between Voyager Therapeutics, Inc. (the “Company”) and Omar Khwaja, MD, PhD, (the “Executive”).
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. TERMINATION AGREEMENTTermination Agreement • August 9th, 2019 • Voyager Therapeutics, Inc. • Biological products, (no disgnostic substances)
This TERMINATION AGREEMENT (the “Agreement”), is entered into as of June 14, 2019 (the “Agreement Date”), to terminate that certain Collaboration Agreement, dated February 11, 2015, as amended by Amendment No. 1 to Collaboration Agreement, dated March 28, 2017 (together, the “Collaboration Agreement”), by and between Voyager Therapeutics, Inc., a corporation organized and existing under the laws of Delaware (“Voyager”), and Genzyme Corporation, a corporation organized and existing under the laws of the Commonwealth of Massachusetts (“Genzyme”). Genzyme and Voyager are each referred to herein as a “Party” and collectively as the “Parties.”
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. AMENDED AND RESTATED OPTION...Option and License Agreement • August 9th, 2019 • Voyager Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This AMENDED AND RESTATED OPTION AND LICENSE AGREEMENT (this “Agreement”) is made and entered into as of June 14, 2019 (the “Effective Date”) by and between Voyager Therapeutics, Inc., a corporation organized and existing under the laws of Delaware (“Voyager”), and Genzyme Corporation, a corporation organized and existing under the laws of the Commonwealth of Massachusetts (“Genzyme”, collectively with Voyager, the “Parties” and each, individually, a “Party”), and amends and restates that certain Non-Exclusive Option and License Agreement by and between Voyager and Genzyme (the “Original Agreement”) dated as of February 11, 2015.
AMENDMENT NO. 1 TO COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • August 9th, 2019 • Voyager Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 1 to Collaboration and License Agreement (the “Amendment”) entered into and effective on June 14, 2019 (the “Amendment Execution Date”), is made by and between Voyager Therapeutics, Inc., a Delaware corporation, having its principal place of business at 75 Sidney Street, Cambridge, MA 02139 (“Voyager”), and Neurocrine Biosciences, Inc., a Delaware corporation, having its principal place of business at 12780 El Camino Real, San Diego, CA 92130 (“Neurocrine”). Voyager and Neurocrine each may be referred to individually as a “Party”, or together as the “Parties” Capitalized terms that are not defined in this Amendment shall have the meaning set forth in the Agreement (as defined below).
CONSULTING AGREEMENTConsulting Agreement • August 9th, 2019 • Voyager Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
THIS AGREEMENT (together with the attached Accounting of Services Form, the “Agreement”), is entered into as of June 28, 2019 (the “Effective Date”), by and between Dinah Sah, (the “Consultant”) and Voyager Therapeutics, Inc., a Delaware corporation located at 75 Sidney Street, Cambridge, MA 02139 (hereinafter “Voyager”).
